Poor response to azithromycin in cutaneous leishmaniasis leading to a premature interruption of a multicentric phase III clinical trial in Brazil
Open Access
- 1 December 2014
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 47 (6) , 756-762
Abstract
Key words: Azithromycin; Cutaneous leishmaniasis; Leishmania braziliensis ; Randomized controlled trial; Meglumine antimoniateKeywords
This publication has 18 references indexed in Scilit:
- Assessment of the quality of life of patients with cutaneous leishmaniasis in Belo Horizonte, Brazil, 2009-2010. A pilot studyTransactions of the Royal Society of Tropical Medicine and Hygiene, 2013
- Leishmaniasis Worldwide and Global Estimates of Its IncidencePLOS ONE, 2012
- Miltefosine and cutaneous leishmaniasisCurrent Opinion in Infectious Diseases, 2012
- High-Dose Oral Fluconazole Therapy Effective for Cutaneous Leishmaniasis Due to Leishmania (Vianna) braziliensisClinical Infectious Diseases, 2011
- Miltefosine: oral treatment of leishmaniasisExpert Review of Anti-infective Therapy, 2006
- Drug Resistance in LeishmaniasisClinical Microbiology Reviews, 2006
- Advances in leishmaniasisThe Lancet, 2005
- Determination of intracellular efficacies of azithromycin against Leishmania major infection in human neutrophils in vitroCell Biochemistry and Function, 2002
- Fluconazole for the Treatment of Cutaneous Leishmaniasis Caused byLeishmania majorNew England Journal of Medicine, 2002
- Treatment of American Cutaneous Leishmaniasis with Miltefosine, an Oral AgentClinical Infectious Diseases, 2001